Rhythm Pharma's Setmelanotide Phase 3 EMANATE Trial Misses Primary Endpoints, Post Hoc Data Shows Promise

summarizeSummary

Rhythm Pharmaceuticals announced that its Phase 3 EMANATE trial for setmelanotide failed to meet its primary endpoints across four substudies, though post hoc analyses revealed statistically significant BMI reductions in two specific patient populations.

check_boxKey Events

• Phase 3 EMANATE Trial Misses Primary Endpoints

  Setmelanotide failed to meet its primary endpoints across all four substudies (POMC/PCSK1 Hets, LEPR Hets, SRC1 (NCOA1), and SH2B1) in the global Phase 3 EMANATE trial.

• Post Hoc Analyses Show Positive Signals

  Despite the primary endpoint miss, post hoc analyses demonstrated statistically significant and clinically meaningful BMI reductions in POMC/PCSK1 Hets and SRC1 (NCOA1) patient populations.

• No New Safety Concerns

  The safety profile of setmelanotide in the EMANATE trial was consistent with prior studies, with no new safety signals observed.

• Future Development Strategy

  Rhythm plans to continue analyzing the EMANATE data and evaluate clinical development paths for SRC1 (NCOA1) and POMC with its next-generation MC4R agonists, bivamelagon and RM-718.

auto_awesomeAnalysis

The failure of setmelanotide to meet primary endpoints in the EMANATE Phase 3 trial is a significant setback for Rhythm Pharmaceuticals, impacting the potential expansion of the drug's label into broader genetically-driven obesity indications. While the post hoc analyses showing statistically significant BMI reductions in POMC/PCSK1 Hets and SRC1 (NCOA1) substudies offer a potential path forward for future development, particularly with next-generation MC4R agonists, the immediate market reaction is likely to be negative due to the primary endpoint miss. Investors will closely monitor the company's detailed plans for these next-generation assets and how these learnings will be integrated into their clinical strategy. The conference call today will be crucial for understanding management's perspective and future direction.